Nilotinib

• Nilotinib acts on BCR‑ABL driven malignancies and is indicated for the following hematologic cancers:
• Chronic myeloid leukemia (CML): provides disease control and prolongs survival in patients with chronic, accelerated, or blast phase disease.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction and maintenance therapy in adult patients with this high‑risk disease.
• CML after imatinib resistance: offers an alternative therapeutic option for patients who have failed first‑generation tyrosine kinase inhibitor therapy.
• CML in blast phase: provides targeted therapy when disease progresses to blast phase.

• Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, as well as the KIT and platelet‑derived growth factor receptors (PDGFR). By blocking these kinases, it prevents phosphorylation of downstream signaling proteins that drive cell proliferation and survival. This inhibition leads to reduced growth of leukemic cells that depend on BCR‑ABL–mediated signaling pathways. The drug’s high affinity for these targets provides greater potency compared with first‑generation inhibitors.

Nilotinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may be watery.
• Rash: skin redness or itching.
• Headache: mild to moderate head pain.
• Fatigue: feeling of tiredness or weakness.
• Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects

• Cardiovascular events: ischemic heart disease, QT‑interval prolongation, arterial occlusive disease.
• Hepatic toxicity: elevated liver enzymes, hepatitis, possible liver failure.
• Pancreatitis: inflammation of the pancreas with abdominal pain.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Serious infections: opportunistic or severe bacterial, viral, or fungal infections.

When prescribing Nilotinib, clinicians should observe several safety precautions to minimize risks.

• Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation or ischemic changes.
• Liver function assessment: check hepatic enzymes before initiation and during therapy for signs of toxicity.
• Pancreatic enzyme monitoring: measure amylase and lipase regularly to identify pancreatitis early.
• Infection vigilance: monitor patients for signs of infection and manage promptly.
• Drug interaction review: avoid concomitant use of strong CYP3A4 inhibitors or inducers without dose adjustment.
• Store at room temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and risk of cardiac events.
• Antacids containing aluminum or magnesium: reduce nilotinib absorption when taken together.
• Proton pump inhibitors (e.g., omeprazole): can lower nilotinib exposure.
• St. John’s wort: a CYP3A4 inducer that decreases drug concentrations.
• Grapefruit juice: CYP3A4 inhibition that may increase nilotinib levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce efficacy of nilotinib.
• Warfarin: nilotinib can affect anticoagulation control, requiring INR monitoring.
• Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy.
• Diuretics: potential electrolyte disturbances when combined.
• Antihypertensive agents: blood pressure may need adjustment.